Introduction: Low-dose CT (LDCT) screening of high-risk smokers reduces lung cancer (LC) specific mortality. Determining screening eligibility using individualised risk may improve screening effectiveness and reduce harm. Here, we compare the performance of two risk prediction models (PLCO and Liverpool Lung Project model (LLP)) and National Lung Screening Trial (NLST) eligibility criteria in a community-based screening programme.

Methods: Ever-smokers aged 55-74, from deprived areas of Manchester, were invited to a Lung Health Check (LHC). Individuals at higher risk (PLCO score ≥1.51%) were offered annual LDCT screening over two rounds. LLP score was calculated but not used for screening selection; ≥2.5% and ≥5% thresholds were used for analysis.

Results: PLCO ≥1.51% selected 56% (n=1429) of LHC attendees for screening. LLP ≥2.5% also selected 56% (n=1430) whereas NLST (47%, n=1188) and LLP ≥5% (33%, n=826) selected fewer. Over two screening rounds 62 individuals were diagnosed with LC; representing 87% (n=62/71) of 6-year incidence predicted by mean PLCO score (5.0%). 26% (n=16/62) of individuals with LC were not eligible for screening using LLP ≥5%, 18% (n=11/62) with NLST criteria and 7% (n=5/62) with LLP ≥2.5%. NLST eligible Manchester attendees had 2.5 times the LC detection rate than NLST participants after two annual screens (≈4.3% (n=51/1188) vs 1.7% (n=438/26 309); p<0.0001). Adverse measures of health, including airflow obstruction, respiratory symptoms and cardiovascular disease, were positively correlated with LC risk. Coronary artery calcification was predictive of LC (OR 2.50, 95% CI 1.11 to 5.64; p=0.028).

Conclusion: Prospective comparisons of risk prediction tools are required to optimise screening selection in different settings. The PLCO model may underestimate risk in deprived UK populations; further research focused on model calibration is required.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402560PMC
http://dx.doi.org/10.1136/thoraxjnl-2020-214626DOI Listing

Publication Analysis

Top Keywords

lung cancer
12
screening
11
ldct screening
8
plco score
8
screening rounds
8
selected 56%
8
screening llp
8
llp ≥5%
8
llp
7
plco
5

Similar Publications

Idiopathic pulmonary fibrosis (IPF) is a fatal disease defined by a progressive decline in lung function due to scarring and accumulation of extracellular matrix (ECM) proteins. The SOCS (Suppressor Of Cytokine Signaling) domain is a 40 amino acid conserved domain known to form a functional ubiquitin ligase complex targeting the Von Hippel Lindau (VHL) protein for proteasomal degradation. Here we show that the SOCS conserved domain operates as a molecular tool, to disrupt collagen and fibronectin fibrils in the ECM associated with fibrotic lung myofibroblasts.

View Article and Find Full Text PDF

Using Fourier Transform Infrared spectroscopy (FTIR), it is possible to show chemical composition of materials and / or profile chemical changes occurring in tissues, cells, and body fluids during onset and progression of diseases. For diagnostic application, the use of blood would be the most appropriate in biospectroscopy studies since, (i) it is easily accessible and, (ii) enables frequent analyses of biochemical changes occurring in pathological states. At present, different studies have investigated potential of serum, plasma and sputum being alternative biofluids for lung cancer detection using FTIR.

View Article and Find Full Text PDF

Micropapillary adenocarcinoma (MPC) is an aggressive histological subtype of lung adenocarcinoma (LUAD). MPC is composed of small clusters of cancer cells exhibiting inverted polarity. However, the mechanism underlying its formation is poorly understood.

View Article and Find Full Text PDF

Evaluating the effectiveness of cancer treatments in relation to specific tumor mutations is essential for improving patient outcomes and advancing the field of precision medicine. Here we represent a comprehensive analysis of 78,287 U.S.

View Article and Find Full Text PDF

The mechanism(s) underlying gut microbial metabolite (GMM) contribution towards alcohol-mediated cardiovascular disease (CVD) is unknown. Herein we observe elevation in circulating phenylacetylglutamine (PAGln), a known CVD-associated GMM, in individuals living with alcohol use disorder. In a male murine binge-on-chronic alcohol model, we confirm gut microbial reorganization, elevation in PAGln levels, and the presence of cardiovascular pathophysiology.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!